middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine
CXSL1700011-Ⅱ
Phase 2 mab active
Quick answer
middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine for Norovirus Infections is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Norovirus Infections
- Phase
- Phase 2
- Modality
- mab
- Status
- active